Key Highlights

  • Cash and cash equivalents were $100.4 million at September 30, 2026.
  • The company dosed the first patient in its SZN-8141 DUET study.
  • Surrozen raised about $29.8 million in net proceeds through an at-the-market program in October 2026.
  • A private Placement Tranche generated about $95.1 million in gross proceeds after the quarter.

Surrozen, Inc. (NASDAQ:SRZN) reported cash and cash equivalents of $100.4 million as of September 30, 2026, and said it has moved into its next stage of development. In October it raised about $29.8 million in net proceeds through its at-the-market program, and after the quarter it generated about $95.1 million in gross proceeds from a tranche of a March 2025 private placement.

Clinical Development Milestone

The first patient dosing in the SZN-8141 DUET study marks the start of clinical testing in the program, which the company described as its next stage.

The company's approach is to target the pathway selectively for specific eye conditions, which is why careful early-stage testing is needed.

Cash Position and Recent Financing

The October at-the-market program added about $29.8 million in net proceeds, and the private placement tranche added about $95.1 million in gross proceeds after deducting placement fees and other offering expenses.

The summary figures do not give the share count effect of these transactions, so that calculation requires the full filing.

Outlook for the Program

That additional funding gives management more time to generate early data from the DUET study before deciding on subsequent steps.

Final Word

Surrozen enters the next phase of development with $100.4 million in cash at quarter end and additional funding raised after the period. The first patient dosed in the SZN-8141 DUET study is the principal milestone reported.